基于人群的类风湿关节炎医疗质量评价指标报告
该研究利用加拿大不列颠哥伦比亚省健康行政数据,纳入1997至2009年38,673例新发和57,922例现患类风湿关节炎患者,随访至2014年,操作化并报告了国家认可的RA绩效指标。研究发现风湿科就诊率和DMARD使用率存在差距,但接受风湿科治疗者的DMARD启用时间有所改善。
要点
- 新发患者365天内风湿科就诊率从2000年35%升至2009年65%
- 现患患者每年风湿科随访率从2001年79%降至2014年39%
- 总人群DMARD配药率2014年仅37%,风湿科管理下为87%
核心结论
- 利用行政数据可操作化报告国家RA绩效指标并识别诊疗差距。
- 风湿科随访率随时间下降,DMARD使用在总人群中仍不理想。
研究设计与样本
- 基于人群的队列研究,使用加拿大不列颠哥伦比亚省健康行政数据。
- 队列含38,673例新发和57,922例现患RA病例。
主要发现
- 新发患者365天内至少1次风湿科就诊比例从2000年35%升至2009年65%。
- 现患患者每年至少1次风湿科就诊比例从2001年79%降至2014年39%,下降源于随访时间延长而非日历效应。
- 总人群DMARD配药率2014年为37%,当前风湿科管理下患者为87%。
- 风湿科就诊者DMARD中位启用时间从2000年49天改善至2009年23天,34%在14天基准内接受治疗。
关键数值与推荐
- 绩效指标包括:新发患者365天内≥1次风湿科就诊比例。
- 绩效指标包括:现患患者每年≥1次风湿科就诊比例。
- 绩效指标包括:现患患者接受DMARD治疗比例及诊断至DMARD启用时间。
- DMARD启用14天为基准,34%的风湿科就诊者在基准内接受治疗。
临床怎么用
- 可利用行政数据常规监测RA诊疗质量并识别未满足的风湿科随访需求。
- 应关注总人群中DMARD使用不足及风湿科随访率下降问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To operationalize and report on nationally endorsed rheumatoid arthritis (RA) performance measures (PMs) using health administrative data for British Columbia (BC), Canada. METHODS: All patients with RA in BC ages ≥18 years were identified between January 1, 1997 and December 31, 2009 using health administrative data and followed until December 2014. PMs tested include: the percentage of incident patients with ≥1 rheumatologist visit within 365 days; the percentage of prevalent patients with ≥1 rheumatologist visit per year; the percentage of prevalent patients dispensed disease-modifying antirheumatic drug (DMARD) therapy; and time from RA diagnosis to DMARD therapy. Measures were reported on patients seen by rheumatologists, and in the total population. RESULTS: The cohort included 38,673 incident and 57,922 prevalent RA cases. The percentage of patients seen by a rheumatologist within 365 days increased over time (35% in 2000 to 65% in 2009), while the percentage of RA patients under the care of a rheumatologist seen yearly declined (79% in 2001 to 39% in 2014). The decline was due to decreasing visit rates with increasing follow-up time rather than calendar effect. The percentage of RA patients dispensed a DMARD was suboptimal over follow-up (37% in 2014) in the total population but higher (87%) in those under current rheumatologist care. The median time to DMARD in those seen by a rheumatologist improved from 49 days in 2000 to 23 days in 2009, with 34% receiving treatment within the 14-day benchmark. CONCLUSION: This study describes the operationalization and reporting of national PMs using administrative data and identifies gaps in care to further examine and address.
引用
- Barber CEH, Marshall DA, Szefer E, et al. A Population-Based Approach to Reporting System-Level Performance Measures for Rheumatoid Arthritis Care. Arthritis Care Res (Hoboken). 2021. PMID: 32144843. doi:10.1002/acr.24178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。